The epidemiological purpose of pharmaceutical industry comprises mainly towards the provision of quality drugs for prevention and intervention of emerging infectious disease (EID). Data gets collected in form of mortality rate, incidence rate and prevalence of the infectious agents.
Emerging infectious diseases (EID) is a type of disease occurring from infections of unknown strains of microorganism. They may also reoccur from infectious diseases that may have occurred many years back. These infectious diseases are either new or have a potential to become epidemic in the near future. Some common examples of the EID include; HIV/AIDS, tuberculosis, Influenza, malaria, dengue, cholera, Ebola, and many others to name (Drotman et al., 2018).
In the last few decades, after the discovery of penicillin, a large number of these diseases have been controlled or eliminated. However, infectious diseases have a tendency to recur in a different population or region than before. This phenomenon is termed as emerging infectious diseases (EID).